Boundless Bio Announces Pipeline and Leadership Updates
Clinical Trial Updates: Boundless Bio has decided not to advance BBI-825 into the second part of the STARMAP clinical trial due to preliminary data and rising development costs, while continuing to focus on BBI-355 and a third ecDTx program with expected milestones extending into 2027.
Leadership Changes: The company announced the departure of Chief Medical Officer Klaus Wagner and Chief Business Officer Neil Abdollahian, with James L. Freddo stepping in as Interim CMO during the transition.
Trade with 70% Backtested Accuracy
Analyst Views on BOLD
About BOLD
About the author
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
POTENTIATE Trial Enrollment: Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of the POTENTIATE trial, expecting to deliver initial proof-of-concept clinical data within its cash runway timeline.
Financial Overview: The company reported a net loss of $15.7 million for Q2 2025, with $127 million in cash supporting operations through expected clinical readouts into 2028.
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Appointment of Carolyn Ng: Carolyn Ng has been appointed to the external advisory board of the Rice Biotech Launch Pad, bringing her extensive experience in biotech and company building to support the accelerator's mission of translating health and medical technology discoveries into effective therapies.
Role of the Rice Biotech Launch Pad: The Rice Biotech Launch Pad aims to expedite the transition of innovative research from Rice University into clinical studies and commercialization, contributing to Houston's growth as a leading biotech hub.